Summary
This Form 8-K filing from Vertex Pharmaceuticals, dated November 27, 2007, reports on significant developments concerning its Aurora kinase inhibitor programs in collaboration with Merck & Co. The most critical announcement is Merck's decision to suspend enrollment in clinical trials for MK-0457 (VX-680) due to preliminary safety data indicating QTc prolongation in one patient. While current patients can continue treatment with enhanced monitoring, this development poses a substantial risk to the drug's progression. Additionally, Vertex and Merck have discontinued the development of MK-6592 (VX-667) due to pharmacokinetic issues identified in a Phase 1 trial. Despite these setbacks, the report also signals a forward-looking step with Merck's intention to initiate a Phase 1 clinical trial for a new Aurora kinase inhibitor, VX-689, in early 2008 for patients with solid tumors. Investors should monitor the outcomes of VX-689 trials and the resolution of safety concerns regarding MK-0457.
Key Highlights
- 1Merck has suspended enrollment in clinical trials for MK-0457 (VX-680), an Aurora kinase inhibitor, due to preliminary safety findings of QTc prolongation.
- 2Current MK-0457 trial participants may continue treatment with increased monitoring for QTc prolongation.
- 3Development of MK-6592 (VX-667), another Aurora kinase inhibitor, has been discontinued due to pharmacokinetic objectives not being met in Phase 1 trials.
- 4Merck plans to initiate a Phase 1 clinical trial for a new Aurora kinase inhibitor, VX-689, in early 2008.
- 5The VX-689 trial will focus on patients with advanced and/or refractory solid tumors.
- 6The company emphasizes that forward-looking statements are subject to risks and uncertainties, including potential adverse outcomes in ongoing studies and unforeseen scientific or business constraints.